Deferasirox Market

Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.

Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.

The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.

Deferasirox Market contains market size and forecasts of Deferasirox in global, including the following market information:

Global Deferasirox Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Deferasirox Market Sales, 2017-2022, 2023-2028, (M Tablets)

Global top five Deferasirox companies in 2021 (%)

The global Deferasirox market was valued at 2808.8 million in 2021 and is projected to reach US$ 3773.2 million by 2028, at a CAGR of 4.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

500 mg/Tablet Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Deferasirox include Novartis, Cipla, Natco Pharma and Sun Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Deferasirox manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Deferasirox Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Tablets)

Global Deferasirox Market Segment Percentages, by Type, 2021 (%)

500 mg/Tablet

250 mg/Tablet

125 mg/Tablet

Others

Global Deferasirox Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Tablets)

Global Deferasirox Market Segment Percentages, by Application, 2021 (%)

Transfusional Iron Overload

NTDT Caused Iron Overload

Global Deferasirox Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Tablets)

Global Deferasirox Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Deferasirox revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Deferasirox revenues share in global market, 2021 (%)

Key companies Deferasirox sales in global market, 2017-2022 (Estimated), (M Tablets)

Key companies Deferasirox sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Cipla

Natco Pharma

Sun Pharma